Document Type : Original Article
Authors
- Elaheh Amirfar 1
- Ehsan Shirvani 2
- Shervin Ghaffari Hoseini 3
- Marjan Mansourian 4
- Shima Aminzadeh 4
- Marjan Jamalian 5
- Alireza Nateghi 6
- Afshin Amirpour 7
- Mohammad kermani-Alghoreaishi 8
- Zahra Teimouri-Jervekani 7
- Jamshid Najafian 1
- Hamid Sanei 1
- Alireza Khosravi-Farsani 9
- Kiyan Heshmt-ghahdarijani 10
- Mozhdeh Askari 11
- Mohammadsadegh Sahebzadeh 7
- Nizal Sarrafzadegan 1
- Hamidreza Roohafza 1
- Masoumeh Sadeghi 7
1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Physical Medicine and Rehabilitation, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
5 Chamran Cardiovascular Medical and Research Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
6 Digestive Disease Research Institute, Tehran University of medical Sciences, Tehran, Iran
7 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
8 Advara Heartcare, Bundaberg Base Hospital, Bundaberg, Queensland, Australia
9 Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
10 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
11 Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States
Abstract
BACKGROUND: Polypill or fixed-dose combination has been recognized as an effective secondary prevention strategy for patients with cardiovascular disease (CVD). This study aimed to evaluate the effectiveness of the polypill on one-year medication adherence, patient satisfaction, and lipid profile control in patients with ST-elevation myocardial infarction (STEMI).
METHODS: This was an open-label, multicentric, randomized clinical trial study of STEMI patients who were prescribed a polypill (Aspirin 81 mg, Atorvastatin 40 mg, Metoprolol Succinate 47.5 mg, and Valsartan 40 mg) versus usual care (continued with separate medications) for secondary prevention. The primary outcome was to compare one-year medication adherence between groups. Other outcomes included comparing patient satisfaction and lipid profile after 12 months of follow-up, as well as identifying predictor factors of medication adherence.
RESULTS: Of 624 STEMI participants, 289 patients were treated with the polypill (79.2% male; mean age 61.67 ± 8.54 years), and 335 patients received usual care (82.7% male; mean age 62.10 ± 9.63 years). After one-year follow-up, no significant differences were detected between groups regarding medication adherence (p-value = 0.351) and cholesterol levels (p-value = 0.808). The polypill strategy was associated with increased patient satisfaction and better control of LDL-C (p-value = 0.043) and HDL-C (p-value < 0.001). Patients with a history of chronic kidney disease (OR: 13.392; p-value = 0.001), cerebrovascular disease (OR: 4.577; p-value = 0.011), and higher waist circumference (OR: 1.01; p-value = 0.002) demonstrated a lower probability of medication adherence. In contrast, in-hospital complications such as arrhythmia (OR: 0.039; p-value = 0.010), bleeding (OR: 0.034; p-value = 0.007), and higher ejection fraction (OR: 0.965; p-value = 0.002) were associated with a higher probability of medication adherence.
CONCLUSION: In STEMI patients, participants treated with polypills were more satisfied and showed better lipid profile control. However, a longer follow-up duration is needed to examine the effectiveness of the polypill on medication adherence in this subgroup.
Keywords
2. Kingma J. Myocardial infarction: An overview of STEMI and NSTEMI physiopathology and treatment. World J Cardiovasc Dis. 2018;8(11):498-517. https://doi.org/10.4236/wjcd.2018.811049
3. Varwani M, Ngunga M, Jeilan M, et al. ST-Segment Elevation Myocardial Infarction (STEMI): A 10-year Review form a primary PCI capable hospital in Tanzania. Res Square. 2024. https://doi.org/10.21203/rs.3.rs-4514601/v1
4. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017 Feb 7;17(1):53. https://doi.org/10.1186/s12872-017-0482-9
5. Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397(10279):1085-94. https://doi.org/10.1016/S0140-6736(21)00272-5
6. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-37. https://doi.org/10.1093/eurheartj/ehab484
7. Rahhal A, Mahfouz A, Khir F, Okleh N, Aljundi AH, AlKhalaila O, et al. Medications adherence post-primary percutaneous coronary intervention in acute myocardial infarction: A population-based cohort study. J Clin Pharm Ther. 2021 Jun;46(3):772-79. https://doi.org/10.1111/jcpt.13348
8. Korol S, Wsół A, Puchalska L, Reshetnik A. Medication adherence and its impact on the average life expectancy after st-segment elevation myocardial infarction: the results of the Ukrainian stimul registry. Wiad Lek. 2022;75(3):563-69.
9. Malachias MVB, Kaiser SE, Albuquerque DCd, Brandão AA, Sposito AC, Moura LZ, et al. Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: a Systematic Review. Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: a Systematic Review. SciELO. 2024; Preprint. https://doi.org/10.1590/SciELOPreprints.9997
10. Kengne AP, Brière JB, Zhu L, Li J, Bhatia MK, Atanasov P, et al. Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review. Expert Rev Pharmacoecon Outcomes Res. 2024 Jan;24(1):143-54. https://doi.org/10.1080/14737167.2023.2266135
11. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28;326(7404):1419. https://doi.org/10.1136/bmj.326.7404.1419
12. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015 Jul;22(7):920-30. https://doi.org/10.1177/2047487314530382
13. Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016 Feb 15;205:147-56. https://doi.org/10.1016/j.ijcard.2015.12.015
14. Thom S, Field J, Poulter N, Patel A, Prabhakaran D, Stanton A, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol. 2014 Feb;21(2):252-61. https://doi.org/10.1177/2047487312463278
15. Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, et al. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials. 2011 Nov;32(6):909-15. https://doi.org/10.1016/j.cct.2011.07.006
16. Sadeghi M, Askari A, Bostan F, Heidari A, Ghasemi G, Alavi Tabatabaei G, et al. Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants. Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102061. https://doi.org/10.1016/j.cpcardiol.2023.102061
17. Cosin-Sales J, Murcia-Zaragoza JM, Pereyra-Rico HO, de la Guia-Galipienso F, Hermans K, Rubio G. PCV135 observational, international, cohort study to evaluate the satisfaction and preferences of patients in preventive treatment of secondary cardiovascular events with a cardiovascular polypill. Value Health. 2019;22:S566-7. https://doi.org/10.1016/j.jval.2019.09.859
18. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-826. https://doi.org/10.1093/eurheartj/ehad191
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
20. Ghobadi P, Gholami M, Hasanvand S, Toulabi T, Moradifar N, Birjandi M. Effects of a multidisciplinary management program on symptom burden and medication adherence in heart failure patients with comorbidities: A randomized controlled trial. BMC Nurs. 2022 Dec 7;21(1):346. https://doi.org/10.1186/s12912-022-01130-7
21. Abdshah A, Parsaeian M, Nasimi M, Ghiasi M. Validating the “Treatment Satisfaction Questionnaire for Medication” in Persian and Evaluating Treatment Satisfaction Among Patients With Psoriasis. Value Health Reg Issues. 2022 May;29:16-20. https://doi.org/10.1016/j.vhri.2021.06.008
22. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Sep 15;387(11):967-77. https://doi.org/10.1056/nejmoa2208275
23. Villalobos-Pedroza M, Hernandez-Pastrana S, Arias-Mendoza A, Latapi-Ruiz Esparza X, Robles-Ledesma M, Guerrero-Ochoa A, et al. Adherence to optimal medical therapy and control of cardiovascular risk factors in patients after ST elevation myocardial infarction in Mexico. Front Cardiovasc Med. 2024 Jul 23;11:1384684. https://doi.org/10.3389/fcvm.2024.1384684
24. Sadeghi M, Hoseini SG, Nateghi A, Sarrafzadegan N, Mansoorian M, Najafian J, et al. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial. Curr Probl Cardiol. 2022 Jun;47(6):100872. https://doi.org/10.1016/j.cpcardiol.2021.100872
25. Cosin-Sales J, Murcia-Zaragoza JM, Pereyra-Rico HO, la Guía-Galipienso F, Hermans K, Rubio G. Evaluating patients’ satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study. J Comp Eff Res. 2021 Sep;10(13):975-85. https://doi.org/10.2217/cer-2021-0105
26. Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Can J Cardiol. 2021 May;37(5):733-43. https://doi.org/10.1016/j.cjca.2021.02.009
27. Zhao X, Wang D, Qin L. Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2021 Feb 3;21(1):69. https://doi.org/10.1186/s12872-020-01835-0
28. Oh GC, Han JK, Han KH, Hyon MS, Doh JH, Kim MH, et al. Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study. Clin Ther. 2018 May;40(5):676-691.e1. https://doi.org/10.1016/j.clinthera.2018.03.010
29. de Abreu-Silva EO, Siepmann M, Siepmann T. Polypills in the Management of Cardiovascular Risk-A Perspective. J Clin Med. 2024 Sep 16;13(18):5487. https://doi.org/10.3390/jcm13185487
30. Rivera A, Campos B, Ceolin S, Godoi A, Castanha E, Campello Jorge CA, et al. Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2023 Nov 9;30(16):1828-37. https://doi.org/10.1093/eurjpc/zwad245
31. Hennawi HA, Ashraf MT, Zohaib M, Khan MK, Khan IA, Muhammadzai HZU, et al. Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Curr Probl Cardiol. 2023 Aug;48(8):101735. https://doi.org/10.1016/j.cpcardiol.2023.101735
32. Dalmau R, Cordero A, Masana L, Ruiz E, Sicras-Mainar A, González-Juanatey JR. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease. Eur Heart J Open. 2024 Apr 2;4(2):oeae027. https://doi.org/10.1093/ehjopen/oeae027
33. Chávez Fernández JA, Ramírez Mendoza M, Kassck Ipinaa H, Sánchez Ángeles LA, González Chávez A, Escobedo G, Méndez-García LA. The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study. PLoS One. 2023 Aug 25;18(8):e0290544. https://doi.org/10.1371/journal.pone.0290544
34. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82. https://doi.org/10.1016/j.jacc.2014.08.021
35. Jain D, Aggarwal H, Meel S. Assessment of medication adherence in chronic kidney disease patients: a tertiary care experience. Int J Health Sci Res. 2018;8(11):20-30.
36. Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant. 2015 Jan;30(1):39-44. https://doi.org/10.1093/ndt/gfu015
37. Tanashyan M, Antonova K, Lagoda O, Kornilova A, Shchukina E. Adherence to treatment in patients with cerebrovascular disease as a multifactorial problem. Neurol Neuropsychiatr Psychosom. 2023;15(1):18-27. https://doi.org/10.14412/2074-2711-2023-1-18-27
38. Kvarnström K, Westerholm A, Airaksinen M, Liira H. Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research. Pharmaceutics. 2021 Jul 20;13(7):1100. https://doi.org/10.3390/pharmaceutics13071100
39. Giacobbe F, Giannino G, Annone U, Morena A, Di Vita U, Carmagnola L, et al. Impact of statin adherence and interruption within 6 months after ST-segment elevation myocardial infarction (STEMI): Results from the real-world regional registry FAST-STEMI. Int J Cardiol. 2024 Jun 15;405:131933. https://doi.org/10.1016/j.ijcard.2024.131933
40. Watanabe N, Takagi K, Tanaka A, Yoshioka N, Morita Y, Yoshida R, et al. Ten-Year Mortality in Patients With ST-Elevation Myocardial Infarction. Am J Cardiol. 2021 Jun 15;149:9-15. https://doi.org/10.1016/j.amjcard.2021.03.008
41. Ferrante G, Barbieri L, Sponzilli C, Lucreziotti S, Salerno Uriarte D, Centola M, et al. Predictors of Mortality and Long-Term Outcome in Patients with Anterior STEMI: Results from a Single Center Study. J Clin Med. 2021 Nov 29;10(23):5634. https://doi.org/10.3390/jcm10235634
)